Almirall has a product pipeline with projects at different phases of development to address unmet medical needs within our therapeutic areas of interest.
R&D
Pipeline (products in development)
Medicines discovered and developed by Almirall scientists
- Almotriptan
- Ebastine
- Aceclofenac
- Almagate
- Piketoprofen
- Cinitapride
- Clebopride
Almirall carries out its clinical trials according to local regulations in the countries where the trials are performed and following international declarations and guidelines, Declaration of Helsinki and Good Clinical Practices.
The Declaration of Helsinki objective is to guarantee the rights of the clinical trial participants.
Good Clinical Practice (GCPs) is an international ethical and scientific quality standard to ensure the safety and well being of the clinical trial participants and the quality of the results.
The GCP guideline was issued by the International Conference on Harmonisation (ICH), with Health Authority representatives from Europe, the US and Japan and the pharmaceutical industry.
Almirall performs global and complex clinical trials efficiently in terms of time and quality, relying on our scientific and ethical standards and a profound knowledge in the clinical development of new pharmaceutical products.
Optimized for Internet Explorer